CombiMatrix Granted Conditional Approval From New York State Department of Health to Market Prenatal Miscarriage Analysis Test

CombiMatrix Granted Conditional Approval From New York State Department of
Health to Market Prenatal Miscarriage Analysis Test

Opens Large New Market for Leading Growth Product

IRVINE, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for developmental disorders and cancer diagnostics, today announced
that its chromosomal microarray analysis (CMA) test for miscarriage analysis
has received conditional approval from the New York State's Department of
Health for testing on patient samples from the state. With nearly 20 million
people, New York is the third most populated state in the nation, behind only
California and Texas.

The Company's CMA test for miscarriage analysis, also called a Product of
Conception (POC) test, is currently CombiMatrix's fastest growing test in
terms of volumes. CombiMatrix previously announced on June 18^th that volumes
from both of its prenatal CMA tests have increased significantly in the past
six months following the publication of data from two National Institutes of
Health (NIH) studies showing the superiority of CMA over traditional
karyotyping for identifying clinically significant genetic abnormalities.

"Gaining the conditional license and ultimately the final approval to market
and sell our POC test throughout New York is an important milestone for us
that will allow us to broaden the market for our number one growth product,"
said CEO Mark McDonough. "As approved under the conditional license, we will
now begin to sell directly to customers and to seek distribution partnerships
to leverage our internal sales force. This could be a tremendous opportunity
for us and, we believe, for the physicians and patients in New York."

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care – specializing
in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers
comprehensive testing services for the detection of abnormalities of genes at
the DNA level beyond what can be identified through traditional technologies.
The Company performs genetic testing utilizing microarray, FISH, PCR and
G-Band chromosome analyses. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and include, but are
not limited to, statements regarding the advantages and efficacy of CMA over
standard karyotyping.These forward-looking statements are not guarantees of
future results and are subject to risks, uncertainties and assumptions that
could cause our actual results to differ materially and adversely from those
expressed in any forward-looking statement.The risks and uncertainties
referred to above include, but are not limited to:market acceptance of CMA as
a preferred method over karyotyping; the rate of transition to CMA from
karyotyping; our ability to successfully expand the base of our customers and
strategic partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related reports, optimize
the reimbursements received for our testing services, and increase operating
margins by improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer rosters in
both developmental medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets; changes in
demand for our future products; legislative, regulatory and competitive
developments; general economic conditions; and various other factors.Further
information on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q,
and in other filings with the Securities and Exchange Commission.We undertake
no obligation to revise or update publicly any forward-looking statements for
any reason, except as required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

CombiMatrix Corporation
 
Press spacebar to pause and continue. Press esc to stop.